Glycostem developed the world's first GMP compliant manufacturing platform ready for industrial scale-up, providing allogeneic cells for cancer immunotherapy. To further advance the lead in allogeneic cell therapy using oNKord® or sDCord®, Glycostem initiated a Series A financing round to realize the following plans:
- Preparation and execution of an oNKord® pivotal phase II study in AML
- Boosting clinical development in other indications
- Implement and validate up-scaling of production technology in a state-of-the-art facility
Glycostem's products or production platform are available for licensing, enabling partnerships to develop combination therapies or second generation products.